GSK: acquires IDRx
(CercleFinance.com) - GSK announces that it has completed the acquisition of IDRx, a clinical-stage biopharmaceutical company specialising in targeted therapies for gastrointestinal stromal tumors (GIST).
The transaction includes IDRX-42, a highly selective tyrosine kinase inhibitor aimed at improving the management of GIST patients, by targeting all relevant KIT mutations.
Hesham Abdullah, Senior Vice President, Global Head of Oncology R&D, says that GSK plans to develop IDRX-42 as a second-line treatment.
The transaction is worth $1.15bn, of which $1bn will be paid immediately and up to $150m in contingent payments.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The transaction includes IDRX-42, a highly selective tyrosine kinase inhibitor aimed at improving the management of GIST patients, by targeting all relevant KIT mutations.
Hesham Abdullah, Senior Vice President, Global Head of Oncology R&D, says that GSK plans to develop IDRX-42 as a second-line treatment.
The transaction is worth $1.15bn, of which $1bn will be paid immediately and up to $150m in contingent payments.
Copyright (c) 2025 CercleFinance.com. All rights reserved.